These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 26244785)

  • 1. Comparative Metabolomic and Lipidomic Analysis of Phenotype Stratified Prostate Cells.
    Burch TC; Isaac G; Booher CL; Rhim JS; Rainville P; Langridge J; Baker A; Nyalwidhe JO
    PLoS One; 2015; 10(8):e0134206. PubMed ID: 26244785
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epithelial-to-mesenchymal transition involves triacylglycerol accumulation in DU145 prostate cancer cells.
    Dalmau N; Jaumot J; Tauler R; Bedia C
    Mol Biosyst; 2015 Dec; 11(12):3397-406. PubMed ID: 26474270
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metabolomic profiling for the identification of novel diagnostic markers in prostate cancer.
    Lucarelli G; Rutigliano M; Galleggiante V; Giglio A; Palazzo S; Ferro M; Simone C; Bettocchi C; Battaglia M; Ditonno P
    Expert Rev Mol Diagn; 2015; 15(9):1211-24. PubMed ID: 26174441
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Integration of Metabolomics and Transcriptomics Reveals Major Metabolic Pathways and Potential Biomarker Involved in Prostate Cancer.
    Ren S; Shao Y; Zhao X; Hong CS; Wang F; Lu X; Li J; Ye G; Yan M; Zhuang Z; Xu C; Xu G; Sun Y
    Mol Cell Proteomics; 2016 Jan; 15(1):154-63. PubMed ID: 26545398
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Integration of tissue metabolomics, transcriptomics and immunohistochemistry reveals ERG- and gleason score-specific metabolomic alterations in prostate cancer.
    Meller S; Meyer HA; Bethan B; Dietrich D; Maldonado SG; Lein M; Montani M; Reszka R; Schatz P; Peter E; Stephan C; Jung K; Kamlage B; Kristiansen G
    Oncotarget; 2016 Jan; 7(2):1421-38. PubMed ID: 26623558
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel lipogenic enzyme ELOVL7 is involved in prostate cancer growth through saturated long-chain fatty acid metabolism.
    Tamura K; Makino A; Hullin-Matsuda F; Kobayashi T; Furihata M; Chung S; Ashida S; Miki T; Fujioka T; Shuin T; Nakamura Y; Nakagawa H
    Cancer Res; 2009 Oct; 69(20):8133-40. PubMed ID: 19826053
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Variable metastatic potentials correlate with differential plectin and vimentin expression in syngeneic androgen independent prostate cancer cells.
    Burch TC; Watson MT; Nyalwidhe JO
    PLoS One; 2013; 8(5):e65005. PubMed ID: 23717685
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association between bivariate expression of key oncogenes and metabolic phenotypes of patients with prostate cancer.
    Khodayari Moez E; Pyne S; Dinu I
    Comput Biol Med; 2018 Dec; 103():55-63. PubMed ID: 30340213
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lipidome and metabolome analysis of fresh tobacco leaves in different geographical regions using liquid chromatography-mass spectrometry.
    Li L; Lu X; Zhao J; Zhang J; Zhao Y; Zhao C; Xu G
    Anal Bioanal Chem; 2015 Jul; 407(17):5009-20. PubMed ID: 25701418
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery of potential biomarkers in human melanoma cells with different metastatic potential by metabolic and lipidomic profiling.
    Kim HY; Lee H; Kim SH; Jin H; Bae J; Choi HK
    Sci Rep; 2017 Aug; 7(1):8864. PubMed ID: 28821754
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phenotypic malignant changes and untargeted lipidomic analysis of long-term exposed prostate cancer cells to endocrine disruptors.
    Bedia C; Dalmau N; Jaumot J; Tauler R
    Environ Res; 2015 Jul; 140():18-31. PubMed ID: 25817993
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metabolomic signatures of aggressive prostate cancer.
    McDunn JE; Li Z; Adam KP; Neri BP; Wolfert RL; Milburn MV; Lotan Y; Wheeler TM
    Prostate; 2013 Oct; 73(14):1547-60. PubMed ID: 23824564
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metabolomic profiling for the identification of novel diagnostic markers and therapeutic targets in prostate cancer: an update.
    Lucarelli G; Loizzo D; Ferro M; Rutigliano M; Vartolomei MD; Cantiello F; Buonerba C; Di Lorenzo G; Terracciano D; De Cobelli O; Bettocchi C; Ditonno P; Battaglia M
    Expert Rev Mol Diagn; 2019 May; 19(5):377-387. PubMed ID: 30957583
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 1-Pyrroline-5-carboxylate released by prostate Cancer cell inhibit T cell proliferation and function by targeting SHP1/cytochrome c oxidoreductase/ROS Axis.
    Yan Y; Chang L; Tian H; Wang L; Zhang Y; Yang T; Li G; Hu W; Shah K; Chen G; Guo Y
    J Immunother Cancer; 2018 Dec; 6(1):148. PubMed ID: 30545412
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative metabolic and lipidomic profiling of human breast cancer cells with different metastatic potentials.
    Kim HY; Lee KM; Kim SH; Kwon YJ; Chun YJ; Choi HK
    Oncotarget; 2016 Oct; 7(41):67111-67128. PubMed ID: 27564096
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of D-allose on prostate cancer cell lines: phospholipid profiling by nanoflow liquid chromatography-tandem mass spectrometry.
    Jeong RU; Lim S; Kim MO; Moon MH
    Anal Bioanal Chem; 2011 Aug; 401(2):689-98. PubMed ID: 21633842
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Regulatory Role of mir-203 in Prostate Cancer Progression and Metastasis.
    Saini S; Majid S; Yamamura S; Tabatabai L; Suh SO; Shahryari V; Chen Y; Deng G; Tanaka Y; Dahiya R
    Clin Cancer Res; 2011 Aug; 17(16):5287-98. PubMed ID: 21159887
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differential regulation of metabolic pathways by androgen receptor (AR) and its constitutively active splice variant, AR-V7, in prostate cancer cells.
    Shafi AA; Putluri V; Arnold JM; Tsouko E; Maity S; Roberts JM; Coarfa C; Frigo DE; Putluri N; Sreekumar A; Weigel NL
    Oncotarget; 2015 Oct; 6(31):31997-2012. PubMed ID: 26378018
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gene profiling and pathway analysis of neuroendocrine transdifferentiated prostate cancer cells.
    Mori R; Xiong S; Wang Q; Tarabolous C; Shimada H; Panteris E; Danenberg KD; Danenberg PV; Pinski JK
    Prostate; 2009 Jan; 69(1):12-23. PubMed ID: 18814146
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential protein synthesis and expression levels in normal and neoplastic human prostate cells and their regulation by type I and II interferons.
    Nagano K; Masters JR; Akpan A; Yang A; Corless S; Wood C; Hastie C; Zvelebil M; Cramer R; Naaby-Hansen S
    Oncogene; 2004 Mar; 23(9):1693-703. PubMed ID: 14647428
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.